FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

March 2, 2023

https://www.globenewswire.com/news-release/2023/03/02/2619075/0/en/FDA-Grants-Orphan-Drug-Designation-to-Temferon-for-Treatment-of-Glioblastoma-Multiforme.html

MILAN and NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Temferon™ for the treatment of glioblastoma multiforme (GBM).

Read more at globenewswire.com

Related news for (GNTA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.